

How to Acquire RYSTIGGO

UCB is committed to helping your patients access RYSTIGGO (rozanolixizumab-noli). RYSTIGGO may be acquired by contacting the following authorized specialty distributors or specialty pharmacies.

Specialty Distributors

RYSTIGGO can be acquired via buy and bill through the following network of authorized specialty distributors. UCB has contracted for extended dating terms with authorized specialty distributors for purchases of RYSTIGGO in 2024.

	P: Phone / F: Fax	Website	Order Entry Number for Vials by NDC Code			
			50474-980-79	50474-981-83	50474-982-84	50474-983-86
ASD Healthcare (ABSG)	P: 800-746-6273 / F: 800-547-9413	www.asdhealthcare.com	10281436	10291247	10291317	10291318
Besse Medical	P: 800-543-2111 / F: 800-543-8695	www.besse.com	10281486	10291314	10291452	10291453
Oncology Supply	P: 800-633-7555 / F: 800-248-8205	www.oncologysupply.com	10281459	10291208	10291319	10291460
BioCareSD [®]	P: 800-304-3064 / F: 602-850-6221	store.biocaresd.com	50474-0980-79	1000771	1000772	1000773
CuraScript SD [®]	P: 877-599-7748 / F: 800-862-6208	www.curascriptsd.com	477273	10005074	10005075	10005076
CardinalHealth™ SPD	P: 877-453-3972 / F: 877-274-9897	specialtyonline.cardinalhealth.com	5860515	5937800	5937818	5937826
CardinalHealth Metro Medical™	P: 877-768-2002 / F: 800-926-3161	www.metromedicalorder.com	980790	981830	982840	983860
McKesson Specialty Health*	P: 855-477-9800 / F: 800-800-5673	mscs.mckesson.com	5015791	5018161	5018162	5018163
McKesson Plasma and Biologics	P: 877-625-2566 / F: 888-752-7626	connect.mckesson.com	2836328	2974277	2974285	2974293

*For multi-specialty customers.

Specialty Pharmacies

The specialty pharmacies listed below have been selected to dispense RYSTIGGO.

	P: Phone / F: Fax	Website
CVS Specialty [®]	P: 800-378-0695 / F: 800-323-2445	www.cvsspecialty.com
KabaFusion	P: 877-577-4844 / F: 877-445-8821	www.kabafusion.com
PANTHERx Rare	P: 833-418-7760 / F: 412-567-6135	www.pantherxrare.com

National Drug Code (NDC) ¹	Description ¹	Quantity ¹	Wholesale Acquisition Price (WAC) ^{2,†}
50474-980-79 / 50474-0980-79 [‡]	280 mg/2 mL (140 mg/mL)	1 vial	\$6,050
50474-981-83 / 50474-0981-83 [‡]	420 mg/3 mL (140 mg/mL)	1 vial	\$9,075
50474-982-84 / 50474-0982-84 [‡]	560 mg/4 mL (140 mg/mL)	1 vial	\$12,100
50474-983-86 / 50474-0983-86 [‡]	840 mg/6 mL (140 mg/mL)	1 vial	\$18,150

[†]The price of RYSTIGGO is \$21.61 per mg.²

[‡]For certain purposes, including the proper billing of drug products, an 11-digit NDC may be required.

INDICATION

RYSTIGGO (rozanolixizumab-noli) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

IMPORTANT SAFETY INFORMATION

RYSTIGGO is associated with important warnings and precautions, including increase risk of infection, drug-induced aseptic meningitis, and hypersensitivity reactions. The most common adverse reactions (≥10%) in patients with gMG are headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea.

Please refer to the next page for additional Important Safety Information.

Please refer to the full Prescribing Information provided by the UCB representative and visit RYSTIGGOhcp.com.

How to Acquire RYSTIGGO (cont'd)

Storage and Handling¹



- **Store vials refrigerated** at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light until time of use. Do not freeze. Do not shake
- If needed, vials **may be stored at room temperature** up to 77°F (25°C) for a **single period of up to 30 days** in the original carton to protect the vial from light
- Once a vial has been stored at room temperature, **it should not be returned to the refrigerator**
- The discard date is 30 days after removal of the vial from the refrigerator. **Write the discard date in the space provided on the carton**
- **Discard** the vial if not used **within 30 days** or if the **expiration date has passed**, whichever occurs first

Patient Support

If you have questions about getting your RYSTIGGO patients started in the ONWARD™ Patient Support Program, please visit ucbONWARD.com to access resources for healthcare professionals or contact your Rare Reimbursement Executive for assistance.



ONWARD is provided as a service of UCB and is intended to support the appropriate use of UCB medicines. ONWARD may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infections: RYSTIGGO may increase the risk of infection. Delay RYSTIGGO administration in patients with an active infection until the infection is resolved. During treatment with RYSTIGGO, monitor for clinical signs and symptoms of infection. If serious infection occurs, administer appropriate treatment and consider withholding RYSTIGGO until the infection has resolved.

Immunization

Immunization with vaccines during RYSTIGGO treatment has not been studied. The safety of immunization with live or live-attenuated vaccines and the response to immunization with any vaccine are unknown. Because RYSTIGGO causes a reduction in IgG levels, vaccination with live-attenuated or live vaccines is not recommended during treatment with RYSTIGGO. Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with RYSTIGGO.

Aseptic Meningitis: Serious adverse reactions of aseptic meningitis (also called drug-induced aseptic meningitis) have been reported in patients treated with RYSTIGGO. If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema and rash, were observed in patients treated with RYSTIGGO. Management of hypersensitivity reactions depends on the type and severity of the reaction. Monitor patients during treatment with RYSTIGGO and for 15 minutes after for clinical signs and symptoms of hypersensitivity reactions. If a reaction occurs, institute appropriate measures if needed.

ADVERSE REACTIONS

In a placebo-controlled study, the most common adverse reactions (reported in at least 10% of RYSTIGGO-treated patients) were headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea. Serious infections were reported in 4% of patients treated with RYSTIGGO. Three fatal cases of pneumonia were identified, caused by COVID-19 infection in two patients and an unknown pathogen in one patient. Six cases of infections led to discontinuation of RYSTIGGO.

Please refer to the full Prescribing Information provided by the UCB representative and visit RYSTIGGOhcp.com.

For more information about RYSTIGGO, visit RYSTIGGOhcp.com.

For additional information, contact UCBCares[®] at 1-844-599-CARE (2273).

References: 1. RYSTIGGO [prescribing information]: Smyrna, GA: UCB, Inc. 2. Data on file. UCB, Inc., Smyrna, GA.



RYSTIGGO[®] and UCBCares[®] are registered trademarks, and ONWARD[™] is a trademark, of the UCB Group of Companies. All other trademarks are the property of their respective holders.
©2024 UCB, Inc., Smyrna, GA 30080. All rights reserved.
US-RZ-2400222 | July 2024